Loading…
MEN1 Deficiency‐Driven Activation of the β‐Catenin‐MGMT Axis Promotes Pancreatic Neuroendocrine Tumor Growth and Confers Temozolomide Resistance
O6‐methylguanine DNA methyltransferase (MGMT) removes alkyl adducts from the guanine O6 position (O6‐MG) and repairs DNA damage. High MGMT expression results in poor response to temozolomide (TMZ). However, the biological importance of MGMT and the mechanism underlying its high expression in pancrea...
Saved in:
Published in: | Advanced science 2024-09, Vol.11 (35), p.e2308417-n/a |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | cdi_FETCH-LOGICAL-c4157-b4b4ed1704bda4eed24a2d163dc5c9502293eaa7a507d38e9bbf45523bee71b63 |
container_end_page | n/a |
container_issue | 35 |
container_start_page | e2308417 |
container_title | Advanced science |
container_volume | 11 |
creator | Xu, Junfeng Lou, Xin Wang, Fei Zhang, Wuhu Xu, Xiaowu Ye, Zeng Zhuo, Qifeng Wang, Yan Jing, Desheng Fan, Guixiong Chen, Xuemin Zhang, Yue Zhou, Chenjie Chen, Jie Qin, Yi Yu, Xianjun Ji, Shunrong |
description | O6‐methylguanine DNA methyltransferase (MGMT) removes alkyl adducts from the guanine O6 position (O6‐MG) and repairs DNA damage. High MGMT expression results in poor response to temozolomide (TMZ). However, the biological importance of MGMT and the mechanism underlying its high expression in pancreatic neuroendocrine tumors (PanNETs) remain elusive. Here, it is found that MGMT expression is highly elevated in PanNET tissues compared with paired normal tissues and negatively associated with progression‐free survival (PFS) time in patients with PanNETs. Knocking out MGMT inhibits cancer cell growth in vitro and in vivo. Ectopic MEN1 expression suppresses MGMT transcription in a manner that depends on β‐Catenin nuclear export and degradation. The Leucine 267 residue of MEN1 is crucial for regulating β‐Catenin‐MGMT axis activation and chemosensitivity to TMZ. Interference with β‐Catenin re‐sensitizes tumor cells to TMZ and significantly reduces the cytotoxic effects of high‐dose TMZ treatment, and MGMT overexpression counteracts the effects of β‐Catenin deficiency. This study reveals the biological importance of MGMT and a new mechanism by which MEN1 deficiency regulates its expression, thus providing a potential combinational strategy for treating patients with TMZ‐resistant PanNETs.
Temozolomide (TMZ) is a first‐in‐class clinical chemotherapeutic drug for the treatment of advanced PanNETs via inducing DNA damage, while MGMT repairs DNA damage and disrupts the TMZ response. This study reveals that MEN1 deficiency induces activation of the β‐Catenin‐MGMT axis, and the restoration of MEN1 or the suppression of β‐Catenin re‐sensitizes PanNETs to TMZ. |
doi_str_mv | 10.1002/advs.202308417 |
format | article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_b9de0dc9db3b4166a7eac67e8116e9ed</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_b9de0dc9db3b4166a7eac67e8116e9ed</doaj_id><sourcerecordid>3083681495</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4157-b4b4ed1704bda4eed24a2d163dc5c9502293eaa7a507d38e9bbf45523bee71b63</originalsourceid><addsrcrecordid>eNqFks1uEzEUhUcIRKvSLUtkiQ2bBHvs-fEKRUkJlZqCILC1_HOncTVjt_ZMSljxCOx4Dx6Eh-BJcEiJWjasfOR77qd77ZNlTwkeE4zzl9Ks4zjHOcU1I9WD7DAnvB7RmrGHd_RBdhzjJcaYFLRipH6cHVCOk-DkMPu-ODknaAaN1Rac3vz6-m0W7BocmujermVvvUO-Qf0K0M8fqTqVPTjrklrMF0s0-Wwjehd853tIQjodIDVpdA5D8OCM18E6QMuh8wHNg7_pV0g6g6beNRAiWkLnv_jWd9YAeg_Rxj5B4En2qJFthOPb8yj7-PpkOX0zOns7P51OzkaakaIaKaYYGFJhpoxkACZnMjekpEYXmhc4zzkFKStZ4MrQGrhSDSuKnCqAiqiSHmWnO67x8lJcBdvJsBFeWvHnwocLIUPapwWhuAFsNDeKKkbKUlYgdVlBTUgJHExivdqxrgbVgdHg-iDbe9D7FWdX4sKvBSEsL3K2nebFLSH46wFiLzobNbStdOCHKNJH07ImjBfJ-vwf66UfgktvJSjBvGQ1Jji5xjuXDj7GAM1-GoLFNkNimyGxz1BqeHZ3h739b2KSge0MN7aFzX9wYjL79IHjuqK_Ab3i2Q4</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3109648010</pqid></control><display><type>article</type><title>MEN1 Deficiency‐Driven Activation of the β‐Catenin‐MGMT Axis Promotes Pancreatic Neuroendocrine Tumor Growth and Confers Temozolomide Resistance</title><source>Open Access: PubMed Central</source><source>Open Access: Wiley-Blackwell Open Access Journals</source><source>Publicly Available Content Database</source><creator>Xu, Junfeng ; Lou, Xin ; Wang, Fei ; Zhang, Wuhu ; Xu, Xiaowu ; Ye, Zeng ; Zhuo, Qifeng ; Wang, Yan ; Jing, Desheng ; Fan, Guixiong ; Chen, Xuemin ; Zhang, Yue ; Zhou, Chenjie ; Chen, Jie ; Qin, Yi ; Yu, Xianjun ; Ji, Shunrong</creator><creatorcontrib>Xu, Junfeng ; Lou, Xin ; Wang, Fei ; Zhang, Wuhu ; Xu, Xiaowu ; Ye, Zeng ; Zhuo, Qifeng ; Wang, Yan ; Jing, Desheng ; Fan, Guixiong ; Chen, Xuemin ; Zhang, Yue ; Zhou, Chenjie ; Chen, Jie ; Qin, Yi ; Yu, Xianjun ; Ji, Shunrong</creatorcontrib><description>O6‐methylguanine DNA methyltransferase (MGMT) removes alkyl adducts from the guanine O6 position (O6‐MG) and repairs DNA damage. High MGMT expression results in poor response to temozolomide (TMZ). However, the biological importance of MGMT and the mechanism underlying its high expression in pancreatic neuroendocrine tumors (PanNETs) remain elusive. Here, it is found that MGMT expression is highly elevated in PanNET tissues compared with paired normal tissues and negatively associated with progression‐free survival (PFS) time in patients with PanNETs. Knocking out MGMT inhibits cancer cell growth in vitro and in vivo. Ectopic MEN1 expression suppresses MGMT transcription in a manner that depends on β‐Catenin nuclear export and degradation. The Leucine 267 residue of MEN1 is crucial for regulating β‐Catenin‐MGMT axis activation and chemosensitivity to TMZ. Interference with β‐Catenin re‐sensitizes tumor cells to TMZ and significantly reduces the cytotoxic effects of high‐dose TMZ treatment, and MGMT overexpression counteracts the effects of β‐Catenin deficiency. This study reveals the biological importance of MGMT and a new mechanism by which MEN1 deficiency regulates its expression, thus providing a potential combinational strategy for treating patients with TMZ‐resistant PanNETs.
Temozolomide (TMZ) is a first‐in‐class clinical chemotherapeutic drug for the treatment of advanced PanNETs via inducing DNA damage, while MGMT repairs DNA damage and disrupts the TMZ response. This study reveals that MEN1 deficiency induces activation of the β‐Catenin‐MGMT axis, and the restoration of MEN1 or the suppression of β‐Catenin re‐sensitizes PanNETs to TMZ.</description><identifier>ISSN: 2198-3844</identifier><identifier>EISSN: 2198-3844</identifier><identifier>DOI: 10.1002/advs.202308417</identifier><identifier>PMID: 39041891</identifier><language>eng</language><publisher>Germany: John Wiley & Sons, Inc</publisher><subject>Animals ; Antineoplastic Agents, Alkylating - pharmacology ; Apoptosis ; beta Catenin - genetics ; beta Catenin - metabolism ; Brain cancer ; Cell cycle ; Cell growth ; Cell Line, Tumor ; Disease Models, Animal ; DNA damage ; DNA methylation ; DNA Modification Methylases - genetics ; DNA Modification Methylases - metabolism ; DNA Repair Enzymes - genetics ; DNA Repair Enzymes - metabolism ; Drug Resistance, Neoplasm - drug effects ; Drug Resistance, Neoplasm - genetics ; Female ; Humans ; Kinases ; Lymphatic system ; Male ; Medical prognosis ; MEN1 ; Metastasis ; MGMT ; Mice ; Mice, Nude ; Mutation ; Neuroendocrine tumors ; Neuroendocrine Tumors - drug therapy ; Neuroendocrine Tumors - genetics ; Neuroendocrine Tumors - metabolism ; Pancreas ; Pancreatic Neoplasms - drug therapy ; Pancreatic Neoplasms - genetics ; Pancreatic Neoplasms - metabolism ; Pancreatic Neoplasms - pathology ; Pancreatic neuroendocrine tumors ; Patients ; Proteins ; Proto-Oncogene Proteins - genetics ; Proto-Oncogene Proteins - metabolism ; Survival analysis ; temozolomide ; Temozolomide - pharmacology ; Transcription factors ; Tumor Suppressor Proteins - genetics ; Tumor Suppressor Proteins - metabolism</subject><ispartof>Advanced science, 2024-09, Vol.11 (35), p.e2308417-n/a</ispartof><rights>2024 The Author(s). Advanced Science published by Wiley‐VCH GmbH</rights><rights>2024 The Author(s). Advanced Science published by Wiley‐VCH GmbH.</rights><rights>2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c4157-b4b4ed1704bda4eed24a2d163dc5c9502293eaa7a507d38e9bbf45523bee71b63</cites><orcidid>0009-0002-0899-4874</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/3109648010/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/3109648010?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,11561,25752,27923,27924,37011,37012,44589,46051,46475,53790,53792,74897</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39041891$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Xu, Junfeng</creatorcontrib><creatorcontrib>Lou, Xin</creatorcontrib><creatorcontrib>Wang, Fei</creatorcontrib><creatorcontrib>Zhang, Wuhu</creatorcontrib><creatorcontrib>Xu, Xiaowu</creatorcontrib><creatorcontrib>Ye, Zeng</creatorcontrib><creatorcontrib>Zhuo, Qifeng</creatorcontrib><creatorcontrib>Wang, Yan</creatorcontrib><creatorcontrib>Jing, Desheng</creatorcontrib><creatorcontrib>Fan, Guixiong</creatorcontrib><creatorcontrib>Chen, Xuemin</creatorcontrib><creatorcontrib>Zhang, Yue</creatorcontrib><creatorcontrib>Zhou, Chenjie</creatorcontrib><creatorcontrib>Chen, Jie</creatorcontrib><creatorcontrib>Qin, Yi</creatorcontrib><creatorcontrib>Yu, Xianjun</creatorcontrib><creatorcontrib>Ji, Shunrong</creatorcontrib><title>MEN1 Deficiency‐Driven Activation of the β‐Catenin‐MGMT Axis Promotes Pancreatic Neuroendocrine Tumor Growth and Confers Temozolomide Resistance</title><title>Advanced science</title><addtitle>Adv Sci (Weinh)</addtitle><description>O6‐methylguanine DNA methyltransferase (MGMT) removes alkyl adducts from the guanine O6 position (O6‐MG) and repairs DNA damage. High MGMT expression results in poor response to temozolomide (TMZ). However, the biological importance of MGMT and the mechanism underlying its high expression in pancreatic neuroendocrine tumors (PanNETs) remain elusive. Here, it is found that MGMT expression is highly elevated in PanNET tissues compared with paired normal tissues and negatively associated with progression‐free survival (PFS) time in patients with PanNETs. Knocking out MGMT inhibits cancer cell growth in vitro and in vivo. Ectopic MEN1 expression suppresses MGMT transcription in a manner that depends on β‐Catenin nuclear export and degradation. The Leucine 267 residue of MEN1 is crucial for regulating β‐Catenin‐MGMT axis activation and chemosensitivity to TMZ. Interference with β‐Catenin re‐sensitizes tumor cells to TMZ and significantly reduces the cytotoxic effects of high‐dose TMZ treatment, and MGMT overexpression counteracts the effects of β‐Catenin deficiency. This study reveals the biological importance of MGMT and a new mechanism by which MEN1 deficiency regulates its expression, thus providing a potential combinational strategy for treating patients with TMZ‐resistant PanNETs.
Temozolomide (TMZ) is a first‐in‐class clinical chemotherapeutic drug for the treatment of advanced PanNETs via inducing DNA damage, while MGMT repairs DNA damage and disrupts the TMZ response. This study reveals that MEN1 deficiency induces activation of the β‐Catenin‐MGMT axis, and the restoration of MEN1 or the suppression of β‐Catenin re‐sensitizes PanNETs to TMZ.</description><subject>Animals</subject><subject>Antineoplastic Agents, Alkylating - pharmacology</subject><subject>Apoptosis</subject><subject>beta Catenin - genetics</subject><subject>beta Catenin - metabolism</subject><subject>Brain cancer</subject><subject>Cell cycle</subject><subject>Cell growth</subject><subject>Cell Line, Tumor</subject><subject>Disease Models, Animal</subject><subject>DNA damage</subject><subject>DNA methylation</subject><subject>DNA Modification Methylases - genetics</subject><subject>DNA Modification Methylases - metabolism</subject><subject>DNA Repair Enzymes - genetics</subject><subject>DNA Repair Enzymes - metabolism</subject><subject>Drug Resistance, Neoplasm - drug effects</subject><subject>Drug Resistance, Neoplasm - genetics</subject><subject>Female</subject><subject>Humans</subject><subject>Kinases</subject><subject>Lymphatic system</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>MEN1</subject><subject>Metastasis</subject><subject>MGMT</subject><subject>Mice</subject><subject>Mice, Nude</subject><subject>Mutation</subject><subject>Neuroendocrine tumors</subject><subject>Neuroendocrine Tumors - drug therapy</subject><subject>Neuroendocrine Tumors - genetics</subject><subject>Neuroendocrine Tumors - metabolism</subject><subject>Pancreas</subject><subject>Pancreatic Neoplasms - drug therapy</subject><subject>Pancreatic Neoplasms - genetics</subject><subject>Pancreatic Neoplasms - metabolism</subject><subject>Pancreatic Neoplasms - pathology</subject><subject>Pancreatic neuroendocrine tumors</subject><subject>Patients</subject><subject>Proteins</subject><subject>Proto-Oncogene Proteins - genetics</subject><subject>Proto-Oncogene Proteins - metabolism</subject><subject>Survival analysis</subject><subject>temozolomide</subject><subject>Temozolomide - pharmacology</subject><subject>Transcription factors</subject><subject>Tumor Suppressor Proteins - genetics</subject><subject>Tumor Suppressor Proteins - metabolism</subject><issn>2198-3844</issn><issn>2198-3844</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNqFks1uEzEUhUcIRKvSLUtkiQ2bBHvs-fEKRUkJlZqCILC1_HOncTVjt_ZMSljxCOx4Dx6Eh-BJcEiJWjasfOR77qd77ZNlTwkeE4zzl9Ks4zjHOcU1I9WD7DAnvB7RmrGHd_RBdhzjJcaYFLRipH6cHVCOk-DkMPu-ODknaAaN1Rac3vz6-m0W7BocmujermVvvUO-Qf0K0M8fqTqVPTjrklrMF0s0-Wwjehd853tIQjodIDVpdA5D8OCM18E6QMuh8wHNg7_pV0g6g6beNRAiWkLnv_jWd9YAeg_Rxj5B4En2qJFthOPb8yj7-PpkOX0zOns7P51OzkaakaIaKaYYGFJhpoxkACZnMjekpEYXmhc4zzkFKStZ4MrQGrhSDSuKnCqAiqiSHmWnO67x8lJcBdvJsBFeWvHnwocLIUPapwWhuAFsNDeKKkbKUlYgdVlBTUgJHExivdqxrgbVgdHg-iDbe9D7FWdX4sKvBSEsL3K2nebFLSH46wFiLzobNbStdOCHKNJH07ImjBfJ-vwf66UfgktvJSjBvGQ1Jji5xjuXDj7GAM1-GoLFNkNimyGxz1BqeHZ3h739b2KSge0MN7aFzX9wYjL79IHjuqK_Ab3i2Q4</recordid><startdate>20240901</startdate><enddate>20240901</enddate><creator>Xu, Junfeng</creator><creator>Lou, Xin</creator><creator>Wang, Fei</creator><creator>Zhang, Wuhu</creator><creator>Xu, Xiaowu</creator><creator>Ye, Zeng</creator><creator>Zhuo, Qifeng</creator><creator>Wang, Yan</creator><creator>Jing, Desheng</creator><creator>Fan, Guixiong</creator><creator>Chen, Xuemin</creator><creator>Zhang, Yue</creator><creator>Zhou, Chenjie</creator><creator>Chen, Jie</creator><creator>Qin, Yi</creator><creator>Yu, Xianjun</creator><creator>Ji, Shunrong</creator><general>John Wiley & Sons, Inc</general><general>John Wiley and Sons Inc</general><general>Wiley</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7XB</scope><scope>88I</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>M2O</scope><scope>M2P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0009-0002-0899-4874</orcidid></search><sort><creationdate>20240901</creationdate><title>MEN1 Deficiency‐Driven Activation of the β‐Catenin‐MGMT Axis Promotes Pancreatic Neuroendocrine Tumor Growth and Confers Temozolomide Resistance</title><author>Xu, Junfeng ; Lou, Xin ; Wang, Fei ; Zhang, Wuhu ; Xu, Xiaowu ; Ye, Zeng ; Zhuo, Qifeng ; Wang, Yan ; Jing, Desheng ; Fan, Guixiong ; Chen, Xuemin ; Zhang, Yue ; Zhou, Chenjie ; Chen, Jie ; Qin, Yi ; Yu, Xianjun ; Ji, Shunrong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4157-b4b4ed1704bda4eed24a2d163dc5c9502293eaa7a507d38e9bbf45523bee71b63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Animals</topic><topic>Antineoplastic Agents, Alkylating - pharmacology</topic><topic>Apoptosis</topic><topic>beta Catenin - genetics</topic><topic>beta Catenin - metabolism</topic><topic>Brain cancer</topic><topic>Cell cycle</topic><topic>Cell growth</topic><topic>Cell Line, Tumor</topic><topic>Disease Models, Animal</topic><topic>DNA damage</topic><topic>DNA methylation</topic><topic>DNA Modification Methylases - genetics</topic><topic>DNA Modification Methylases - metabolism</topic><topic>DNA Repair Enzymes - genetics</topic><topic>DNA Repair Enzymes - metabolism</topic><topic>Drug Resistance, Neoplasm - drug effects</topic><topic>Drug Resistance, Neoplasm - genetics</topic><topic>Female</topic><topic>Humans</topic><topic>Kinases</topic><topic>Lymphatic system</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>MEN1</topic><topic>Metastasis</topic><topic>MGMT</topic><topic>Mice</topic><topic>Mice, Nude</topic><topic>Mutation</topic><topic>Neuroendocrine tumors</topic><topic>Neuroendocrine Tumors - drug therapy</topic><topic>Neuroendocrine Tumors - genetics</topic><topic>Neuroendocrine Tumors - metabolism</topic><topic>Pancreas</topic><topic>Pancreatic Neoplasms - drug therapy</topic><topic>Pancreatic Neoplasms - genetics</topic><topic>Pancreatic Neoplasms - metabolism</topic><topic>Pancreatic Neoplasms - pathology</topic><topic>Pancreatic neuroendocrine tumors</topic><topic>Patients</topic><topic>Proteins</topic><topic>Proto-Oncogene Proteins - genetics</topic><topic>Proto-Oncogene Proteins - metabolism</topic><topic>Survival analysis</topic><topic>temozolomide</topic><topic>Temozolomide - pharmacology</topic><topic>Transcription factors</topic><topic>Tumor Suppressor Proteins - genetics</topic><topic>Tumor Suppressor Proteins - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Xu, Junfeng</creatorcontrib><creatorcontrib>Lou, Xin</creatorcontrib><creatorcontrib>Wang, Fei</creatorcontrib><creatorcontrib>Zhang, Wuhu</creatorcontrib><creatorcontrib>Xu, Xiaowu</creatorcontrib><creatorcontrib>Ye, Zeng</creatorcontrib><creatorcontrib>Zhuo, Qifeng</creatorcontrib><creatorcontrib>Wang, Yan</creatorcontrib><creatorcontrib>Jing, Desheng</creatorcontrib><creatorcontrib>Fan, Guixiong</creatorcontrib><creatorcontrib>Chen, Xuemin</creatorcontrib><creatorcontrib>Zhang, Yue</creatorcontrib><creatorcontrib>Zhou, Chenjie</creatorcontrib><creatorcontrib>Chen, Jie</creatorcontrib><creatorcontrib>Qin, Yi</creatorcontrib><creatorcontrib>Yu, Xianjun</creatorcontrib><creatorcontrib>Ji, Shunrong</creatorcontrib><collection>Open Access: Wiley-Blackwell Open Access Journals</collection><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Open Access: DOAJ - Directory of Open Access Journals</collection><jtitle>Advanced science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Xu, Junfeng</au><au>Lou, Xin</au><au>Wang, Fei</au><au>Zhang, Wuhu</au><au>Xu, Xiaowu</au><au>Ye, Zeng</au><au>Zhuo, Qifeng</au><au>Wang, Yan</au><au>Jing, Desheng</au><au>Fan, Guixiong</au><au>Chen, Xuemin</au><au>Zhang, Yue</au><au>Zhou, Chenjie</au><au>Chen, Jie</au><au>Qin, Yi</au><au>Yu, Xianjun</au><au>Ji, Shunrong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>MEN1 Deficiency‐Driven Activation of the β‐Catenin‐MGMT Axis Promotes Pancreatic Neuroendocrine Tumor Growth and Confers Temozolomide Resistance</atitle><jtitle>Advanced science</jtitle><addtitle>Adv Sci (Weinh)</addtitle><date>2024-09-01</date><risdate>2024</risdate><volume>11</volume><issue>35</issue><spage>e2308417</spage><epage>n/a</epage><pages>e2308417-n/a</pages><issn>2198-3844</issn><eissn>2198-3844</eissn><abstract>O6‐methylguanine DNA methyltransferase (MGMT) removes alkyl adducts from the guanine O6 position (O6‐MG) and repairs DNA damage. High MGMT expression results in poor response to temozolomide (TMZ). However, the biological importance of MGMT and the mechanism underlying its high expression in pancreatic neuroendocrine tumors (PanNETs) remain elusive. Here, it is found that MGMT expression is highly elevated in PanNET tissues compared with paired normal tissues and negatively associated with progression‐free survival (PFS) time in patients with PanNETs. Knocking out MGMT inhibits cancer cell growth in vitro and in vivo. Ectopic MEN1 expression suppresses MGMT transcription in a manner that depends on β‐Catenin nuclear export and degradation. The Leucine 267 residue of MEN1 is crucial for regulating β‐Catenin‐MGMT axis activation and chemosensitivity to TMZ. Interference with β‐Catenin re‐sensitizes tumor cells to TMZ and significantly reduces the cytotoxic effects of high‐dose TMZ treatment, and MGMT overexpression counteracts the effects of β‐Catenin deficiency. This study reveals the biological importance of MGMT and a new mechanism by which MEN1 deficiency regulates its expression, thus providing a potential combinational strategy for treating patients with TMZ‐resistant PanNETs.
Temozolomide (TMZ) is a first‐in‐class clinical chemotherapeutic drug for the treatment of advanced PanNETs via inducing DNA damage, while MGMT repairs DNA damage and disrupts the TMZ response. This study reveals that MEN1 deficiency induces activation of the β‐Catenin‐MGMT axis, and the restoration of MEN1 or the suppression of β‐Catenin re‐sensitizes PanNETs to TMZ.</abstract><cop>Germany</cop><pub>John Wiley & Sons, Inc</pub><pmid>39041891</pmid><doi>10.1002/advs.202308417</doi><tpages>21</tpages><orcidid>https://orcid.org/0009-0002-0899-4874</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2198-3844 |
ispartof | Advanced science, 2024-09, Vol.11 (35), p.e2308417-n/a |
issn | 2198-3844 2198-3844 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_b9de0dc9db3b4166a7eac67e8116e9ed |
source | Open Access: PubMed Central; Open Access: Wiley-Blackwell Open Access Journals; Publicly Available Content Database |
subjects | Animals Antineoplastic Agents, Alkylating - pharmacology Apoptosis beta Catenin - genetics beta Catenin - metabolism Brain cancer Cell cycle Cell growth Cell Line, Tumor Disease Models, Animal DNA damage DNA methylation DNA Modification Methylases - genetics DNA Modification Methylases - metabolism DNA Repair Enzymes - genetics DNA Repair Enzymes - metabolism Drug Resistance, Neoplasm - drug effects Drug Resistance, Neoplasm - genetics Female Humans Kinases Lymphatic system Male Medical prognosis MEN1 Metastasis MGMT Mice Mice, Nude Mutation Neuroendocrine tumors Neuroendocrine Tumors - drug therapy Neuroendocrine Tumors - genetics Neuroendocrine Tumors - metabolism Pancreas Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - genetics Pancreatic Neoplasms - metabolism Pancreatic Neoplasms - pathology Pancreatic neuroendocrine tumors Patients Proteins Proto-Oncogene Proteins - genetics Proto-Oncogene Proteins - metabolism Survival analysis temozolomide Temozolomide - pharmacology Transcription factors Tumor Suppressor Proteins - genetics Tumor Suppressor Proteins - metabolism |
title | MEN1 Deficiency‐Driven Activation of the β‐Catenin‐MGMT Axis Promotes Pancreatic Neuroendocrine Tumor Growth and Confers Temozolomide Resistance |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T23%3A13%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=MEN1%20Deficiency%E2%80%90Driven%20Activation%20of%20the%20%CE%B2%E2%80%90Catenin%E2%80%90MGMT%20Axis%20Promotes%20Pancreatic%20Neuroendocrine%20Tumor%20Growth%20and%20Confers%20Temozolomide%20Resistance&rft.jtitle=Advanced%20science&rft.au=Xu,%20Junfeng&rft.date=2024-09-01&rft.volume=11&rft.issue=35&rft.spage=e2308417&rft.epage=n/a&rft.pages=e2308417-n/a&rft.issn=2198-3844&rft.eissn=2198-3844&rft_id=info:doi/10.1002/advs.202308417&rft_dat=%3Cproquest_doaj_%3E3083681495%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4157-b4b4ed1704bda4eed24a2d163dc5c9502293eaa7a507d38e9bbf45523bee71b63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3109648010&rft_id=info:pmid/39041891&rfr_iscdi=true |